San Juan, Puerto Rico, February 21, 2018 – Green Spirit Industries Inc. (OTC Pink: GSRX) (“Green Spirit” or, the “Company”) announced today that Dr. Harlan R., Ribnik, MD has been named to the Company’s Board of Directors, effective immediately.
Dr. Ribnik is a licensed anesthesiologist and pain management specialist actively practicing in Colorado, Wyoming and Idaho. He began private practice in Wyoming in 1989. Since 2005, he has limited his practice to pain management. In addition to his private practice, Dr. Ribnik is a clinical instructor at the University of Wyoming College of Human Medicine.
“We are pleased and honored to have Dr. Ribnik join the Green Spirit Board of Directors,” said CEO Les Ball. “A longtime advocate for the well-documented pain relief that can be provided by cannabis, Dr. Ribnik will be a valuable asset to the Company as we continue to expand our business to include the cultivation and distribution of cannabis and extractions in states where its use is approved for both recreational and medicinal-only purposes.”
Dr. Ribnik is a Board Certified Diplomate of The American Board of Anesthesiology (the “ABA”) and he also holds a subspecialty certification in Pain Medicine from the ABA. In addition he is a Board Certified Diplomate of the American Board of Interventional Pain Physicians. Dr. Ribnik received a B.A. in Mathematics from the University of Colorado Boulder, an M.S. in Computer Science from the University of Colorado Boulder, and his M.D. from the University of Colorado School of Medicine Denver. He completed his internship in Internal Medicine at the University of Missouri-Columbia and his Residency in Anesthesiology at the University of Colorado Health Sciences Center Denver.
Dr. Ribnik served as a Major in the Medical Corps of the U.S. Army Reserve, and a Major in the Civil Air Patrol. He currently resides in Wyoming.
About Green Spirit Industries Inc.
Green Spirit Industries Inc. (OTC Pink: GSRX), together with its wholly-owned subsidiary, Project 1493, LLC, is in the business of acquiring, developing and operating medical cannabis dispensaries.
This press release contains forward-looking statements. Such statements include statements regarding our expectations, hopes, beliefs or intentions regarding the future, including but not limited to statements regarding our market, strategy, competition, development plans (including acquisitions and expansion), financing, revenues, operations, and compliance with applicable laws. Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in any such statement. Factors that could cause actual results to differ materially from such forward-looking statements include the risks described in greater detail in the following paragraphs. All forward-looking statements in this document are made as of the date hereof, based on information available to us as of the date hereof, and we assume no obligation to update any forward-looking statement except where applicable law requires us to update these statements. Market data used throughout this prospectus is based on published third party reports or the good faith estimates of management, which estimates are based upon their review of internal surveys, independent industry publications and other publicly available information.